Status:
RECRUITING
Autoimmune Blistering Diseases Study
Lead Sponsor:
University of Pennsylvania
Conditions:
Pemphigus Vulgaris
Pemphigus Foliaceus
Eligibility:
All Genders
18+ years
Brief Summary
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches. Clinical trials in pemphigus and BP will require the av...
Detailed Description
The disease severity instruments for pemphigus and BP, the Pemphigus Disease Area Index (PDAI) and the Bullous Pemphigoid Disease Area Index (BPDAI), respectively, have the potential to capture change...
Eligibility Criteria
Inclusion Criteria:
- Gender/Age: Males or females above 18 years old
- Diagnosis: pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid
- Subjects able to give informed consent
Exclusion Criteria:
- Patients who are under age 18 years.
- Patients without pemphigus or pemphigoid diseases
- Penn employees
- Penn students
- Cognitively impaired persons
Key Trial Info
Start Date :
April 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 2 2030
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT02753777
Start Date
April 1 2016
End Date
January 2 2030
Last Update
March 30 2026
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital of the University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States, 19104
2
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
3
University of Pennsylvania, Department of Dermatology
Philadelphia, Pennsylvania, United States, 19104